Since 2014, the research team at the Cancer Research Institute of Ghent University and together with the Pediatric Hematology-Oncology and Stem Cell Transplantation UZ Gent has been conducting a research line in the pediatric AML in which leukemic stem cells were characterized and characteristics of these leukemic stem cells could be assessed by an unfavorable prognosis. In this research project, AML stem cell specific long non-coding RNAs (lncRNAs) were used. In the continuation of this research project, the researchers will provide further evidence that inactivation of AML Stem Cell Institute-specific lncRNAs has therapeutic potential. Thus, in the long term, they aim to improve survival rates, prevent treatment updates and improve the quality of life of patients with AML with these new targeted medications (LNA GapmeRs).